Business
Neurona Therapeutics Presents New Long-Term Clinical Data from NRTX-1001 Cell Therapy Trials at 2025 Annual Meeting of the American Epilepsy Society
- NON-MTS & BILATERAL MTLE: First data reported from non-MTS and bilateral MTLE subjects demo...
About this update from 1cm Inc.
[{"type":"text","content":"Neurona Therapeutics Presents New Long-Term Clinical Data from NRTX-1001 Cell Therapy Trials at 2025 Annual Meeting of the American Epilepsy Society\n\n\n\n\n - NON-MTS & BILATERAL MTLE: First data reported from non-MTS and bilateral MTLE subjects demonstrate robust seizure reduction\n \n\n\n\n\n - LOW DOSE COHORT: 89% median reduction in disabling seizures for unilateral subjects with MTS at the primary efficacy evaluation period of 7-12 months post administration (n=9)\n \n\n\n\n - HIGH DOSE COHORT: 78% median reduction in disabling seizures for unilateral subjects with MTS at interim efficacy evaluation period of 4-6 months post administration (n=9)\n \n\n\n\n - DURABILITY: Several subjects have now surpassed the two-year mark, maintaining substantial seizure reduction\n \n\n\n\n - COGNITION: No significant impairments detected in either dose cohort, with significantly increased test scores for some subjects\n \n\n\n\n - SAFETY: NRTX-1001 continues to be well-tolerated at both high and low doses in bilateral and unilateral MTLE subjects, with and without MTS. No serious adverse events have been attributed to the cell therapy\n \n\n\n\n - PIVOTAL TRIAL: EPIC Phase 3 trial of NRTX-1001 in drug-resistant MTLE is planned to dose first subjects in 1H 2026\n \n\n\n\n SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for disorders of the nervous system, today presented new clinical results from its ongoing Phase 1/2 trials evaluating NRTX-1001, a one-time, allogeneic inhibitory interneuron cell therapy for drug-resistant mesial temporal lobe epilepsy (MTLE). The data were presented at the Annual Meeting of the American Epilepsy Society (AES), taking place December 5-9, 2025, in Atlanta, Georgia.\n \n\n The updates include the first announcement of results from subjects without mesial temporal sclerosis (MTS) and from those with bilateral MTLE, expanding the clinical efficacy dataset for NRTX-1001 across a broader MTLE population. Additionally, several treated subjects have now been followed for more than two years, providing the most mature assessment to date of the therapy’s durability, safety, and impact on seizure burden.\n \n\n “We are delighted to share this expanded 2025 clinical dataset at AES, whic...